The first successful Mab therapies were directed against EGFR (Epidermal Growth Factor Receptors) for the treatment of colorectal cancer and against the related growth factor Her-2 (Erb-2) expressed in a proportion of breast cancers. Here, EGFR is linked to colorectal cancer.